Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old, of any gender
• People diagnosed with extensive-stage small cell lung cancer (a type of lung cancer that has spread), confirmed by a tissue or cell sample test
• People whose first treatment involved a standard combination of a PD-L1 immunotherapy drug plus chemotherapy, and whose cancer responded to or remained stable during that treatment; or people who previously had surgery followed by radiation or chemotherapy, with at least 6 months having passed since that earlier treatment before the extensive-stage diagnosis
• People expected to live at least 12 weeks
• People with a good general physical functioning level (rated 0 or 1 on a standard scale used by doctors to measure how well a patient can carry out daily activities)
• People whose blood test results before starting the trial meet specific levels for blood cell counts, liver function, kidney function, and blood clotting — details to be confirmed with the trial site
• Women who could become pregnant must have a negative pregnancy blood test within 7 days before starting the trial, and both women who could become pregnant and men whose partners could become pregnant must agree to use contraception from the time of signing consent until 24 weeks after the last dose
• People who are willing to take part, sign a consent form, follow the study requirements, and attend follow-up visits

Who may not be able to join:

• People whose lung cancer started as a different type of lung cancer (non-small cell lung cancer) that later changed to small cell, or people whose cancer is a mixed type
• People who have cancer that has spread to the membranes surrounding the brain, or who have brain metastases causing active symptoms — though people with stable, symptom-free brain metastases meeting specific additional conditions may still be considered (confirm with trial site)
• People who have fluid build-up in the chest, abdomen, or around the heart that cannot be controlled and requires repeated draining
• People with a history of certain serious lung conditions, such as idiopathic pulmonary fibrosis, certain types of pneumonia, drug-related lung damage, active tuberculosis, or other moderate to severe lung disease
• People with an active autoimmune disease who have been taking steroid or other immune-suppressing medications within 14 days before the first dose
• People with serious heart or blood vessel conditions, such as significant heart failure, unstable chest pain, unstable abnormal heart rhythms, a heart attack within the past 3 months, or a stroke within the past 3 months
• People who have had another cancer within the past 5 years — though some fully treated cancers (such as certain skin cancers, early-stage cervical cancer, or localised prostate or breast cancer) may still be considered (confirm with trial site)
• People with high blood pressure that cannot be controlled with oral blood pressure medication
• People with significant protein detected in their urine, confirmed by a 24-hour urine test showing more than 1.0 g of protein
• People with a significant risk of bleeding, including recent bleeding episodes, hereditary or acquired bleeding disorders, or people currently taking blood-thinning or anti-clotting medications
• People who have recently had a bowel obstruction or a hole in the digestive tract (within the past 3 months), or people who are unable to swallow tablets normally
• People with certain active infections, including hepatitis B with a high viral load, active hepatitis C infection, or a known history of HIV or AIDS
• People who have had major surgery within 28 days before screening, or who are expected to need major surgery during the trial
• People who have received systemic immune-suppressing drug treatment within 1 week before the first dose (short-term use for managing side effects such as nausea or allergic reactions may be considered with investigator approval)
• People who have received a live vaccine within 28 days before the first dose, or who are expected to need one during the trial
• People with known allergies to the study drugs or their ingredients, or a history of severe allergic reactions to any antibody-based medication
• People who have taken part in another experimental drug study within 4 weeks before starting this trial
• People who have previously had a bone marrow transplant from a donor, or a solid organ transplant
• People who, in the investigator's judgement, have other factors that could affect their safety or ability to complete the study, such as serious other illnesses, mental health conditions requiring combined treatment, or significant social or family circumstances

Important: Always verify eligibility with the trial site directly before applying.